Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q1 FY25 results · Apr–Jun 2024
Torrent Pharmaceuticals reported revenue from operations of ₹2,859.00 crore (up 10.3% from Q1 FY24) and net profit of ₹457.00 crore (up 20.9% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,859.00 | 2,591.00 | +10.3% | 2,745.00 | +4.2% |
| Other income | 24.00 | 34.00 | −29.4% | 31.00 | −22.6% |
| Total income | 2,883.00 | 2,625.00 | +9.8% | 2,776.00 | +3.9% |
| Profit before tax | 656.00 | 531.00 | +23.5% | 631.00 | +4.0% |
| Net profit for the period | 457.00 | 378.00 | +20.9% | 449.00 | +1.8% |
| EPS, basic (₹) | 13.51 | 11.18 | +20.8% | 13.27 | +1.8% |
| Net margin (%) | 16.0 | 14.6 | 16.4 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,438.00 | 2,121.00 | +14.9% | 2,143.00 | +13.8% |
| Other income | 21.00 | 11.00 | +90.9% | 76.00 | −72.4% |
| Total income | 2,459.00 | 2,132.00 | +15.3% | 2,219.00 | +10.8% |
| Profit before tax | 667.00 | 475.00 | +40.4% | 530.00 | +25.8% |
| Net profit for the period | 469.00 | 323.00 | +45.2% | 410.00 | +14.4% |
| EPS, basic (₹) | 13.86 | 9.55 | +45.1% | 12.12 | +14.4% |
| Net margin (%) | 19.2 | 15.2 | 19.1 |
Consolidated
- Filed with BSE
- 24 Jul 2024, 10:20 IST
- Board meeting
- 23 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Jul 2024, 10:20 IST
- Board meeting
- 23 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Audited
- Source
- XBRL filing on BSE